Introduction
The phosphatidylinositol 3-kinase (PI3 K) signalling pathway has emerged as a critical route that regulates multiple cellular processes, including survival and proliferation in many cell types (Brunet et al., 2001) . Downstream targets activated subsequent to PI3 K include PKC isoforms, JNK, Ras, p70 S6 kinase, Rac, and protein kinaseB/Akt kinase (Chung et al., 1994; Burgering and Coffer, 1995; Hawkins et al., 1995; Klippel et al., 1996; Mendez et al., 1997; Duronio et al., 1998) . PKB/Akt has been implicated in PI3K-mediated survival effects Franke et al., 1997; Downward, 1998; Kandel and Hay, 1999) . The transfection of fibroblasts and epithelial cells with constitutively active PI3 K or Akt results in the inhibition of apoptosis induced by c-Myc, UV radiation, TGF-b, and Fas activation (Kauffmann-Zeh et al., 1997; Kulik et al., 1997; Chen et al., 1998; Gibson et al., 1999) . Active Akt kinase can directly phosphorylate and inactivate components of the apoptotic machinery, including caspase 9 (Cardone et al., 1998) , Bad del Peso et al., 1997) , and GSK-3b (Pap and Cooper, 1998) . Several transcription factors including AFX, FKHR, FKHRL1 from the Forkhead family (Brunet et al., 1999; Kops et al., 1999; Rena et al., 1999; Tang et al., 1999) , CREB (Du and Montminy, 1998) , NFkB (Kane et al., 1999; Ozes et al., 1999; Romashkova and Makarov, 1999) , and p53 (Yamaguchi et al., 2001) , are direct or indirect targets of Akt kinase. Members of the Forkhead family are implicated in the regulation of the cell cycle. The overexpression of AFX, FKHRL1, or FKHR causes growth suppression in a variety of cell lines (Medema et al., 2000; Alvarez et al., 2001) . In postmitotic neurons and PC12 cells, phosphorylation of FKHRL1 by Akt can prevent Forkhead-mediated induction of Fas ligand (FasL) expression (Brunet et al., 1999) .
Although numerous clinical studies demonstrated elevated Akt activity in human glioma cells (HaasKogan et al., 1998; Sonoda et al., 2001) , little is known about the regulation of Akt signalling and its targets in glioma cells. The elevated activation of Akt has been attributed to the mutations of the PTEN tumor suppressor, which functions as a PI-(3,4,5)P3 lipid phosphatase and antagonizes PI3 K signalling (Maehama and Dixon, 1998) . Cells bearing PTEN mutation show an elevated level of phosphorylated Akt, increased proliferation, and resistance to numerous apoptotic agents (Stambolic et al., 1998; Sun et al., 1999) .
The Fas (APO-1/CD95) receptor-ligand system plays an important role in the regulation of drug-induced apoptosis (Friesen et al., 1996 ; Herr et al., 1997; Kasibhatla et al., 1998) . The Fas receptor is expressed in primary astrocytic brain tumors, with an increasing incidence of expression in higher-grade tumors (Tachibana et al., 1995) . Induction of the proapoptotic molecules such as FasL in cells expressing Fas receptor is considered as an important pathway of transcriptiondependent apoptosis (Sharma et al., 2000) . Glioma cells are particularly resistant to radiation and chemotherapy and few experimental approaches triggering glioma cell death have been described (Hosli et al., 1998; Galanis and Buckner, 2000) . We have previously demonstrated that cyclosporin A (CSA) inhibits growth and induces apoptotic cell death of C6 glioma cells associated with morphological changes, DNA fragmentation, and caspase-3 activation (Pyrzynska et al., 2002) . CsA-induced apoptosis is associated with a persistent activation of JNK and p38 MAP kinases, activation of the AP-1 transcription factor, and FasL gene promoter (Pyrzynska et al., 2000) . Activation of the FasL gene promoter was only partially AP-1-dependent, which indicated a requirement for other transcription factors.
In the present study, we investigated a possible involvement of Akt/Forkhead signalling in the transcriptional regulation of FasL expression in CsA-induced apoptosis of rat C6 glioma cells. We demonstrated that CsA treatment produces a longlasting inhibition of the Akt activity and subsequent activation of the Forkhead transcription factor. It correlates with transcriptional upregulation of fasL mRNA and surface FasL expression. The inhibition of Akt kinase signalling with LY294002, a pharmacological inhibitor of PI3 K, and induction of Forkhead were not sufficient to induce FasL expression or apoptosis. Overexpression of constitutively active Akt significantly blocked the upregulation of fasL. These results suggest that inhibition of Akt-mediated signalling is necessary and contributes to transcriptional regulation of FasL expression in the apoptosis of glioma cells.
Results

Inhibition of Akt signalling pathway and activation of Forkhead during CsA-induced apoptosis
Phosphorylation of both Thr308 and Ser473 by PI3K is essential for Akt activation (Alessi et al., 1996) . The treatment of C6 glioma cells with 60 mM CsA reduced levels of Akt phosphorylated at the Thr308 and Ser473 (Figure 1a ). The decrease of Akt phosphorylation begins at 12.5-15 h after the treatment and sustained for 48 h. The total Akt protein level was not altered by CsA treatment (Figure 1a) . The blots were reprobed with antibodies recognizing actin proteins to ensure equal protein loading. Multiple immunoblots from two independent experiments were scanned and quantitated. Figure 1b shows the mean level of phosphorylated and total Akt after CsA treatment.
To confirm an inhibitory effect of CsA on the Akt signalling pathway, we measured Akt kinase activity at different times after treatment. Akt was immunoprecipitated with a specific antibody linked to agarose beads and the immune complex was assayed for kinase activity toward GSK-3 fusion peptide. As shown in the Figure  1c , a gradual reduction of Akt activity (indicated by a decrease in the phospho-GSK-3a/b level) was observed starting at 15 h after CsA treatment. Measurement of Akt kinase activity in cellular extracts from cells treated with 30 mM LY294002 for 1 h represents a control. The total Akt level demonstrates equal amounts of immunoprecipitated Akt loaded on the gel. A decrease in the Akt kinase activity correlates temporally with the levels of Akt phosphorylated at the Thr308 and Ser473 measured in the same extracts ( Figure 1c, right panel) .
Several proapoptotic proteins, including Bad, caspase-9, GSK-3b, and Forkhead (Fkhr) transcription factors, have been described as Akt downstream targets mediating apoptosis in neuronal cells (Brunet et al., 2001) . Since the Forkhead protein has been implicated both as Akt target and a potential regulator of FasL expression, we studied the level of phosphorylated Forkhead in CsA-tretaed cells by Western blot analysis. The high level of phoshorylated Forkhead was observed in proliferating glioma cells and CsA treatment resulted in the decrease of Fkhr phosphorylation at the Ser256, with a simultaneous increase in Fkhr protein levels. Western blot analysis carried out on the same protein extracts revealed a constant level of the GSK3b protein phosphorylated at the Ser9 (Figure 2a ). The level of Fkhr protein in nuclear extracts (reflecting its translocation to the nucleus) was slightly elevated at 12.5 h, reaching a maximal level 36-48 h after CsA addition (Figure 2b ).
To study changes in the subcellular localization of Fkhr during CsA-induced apoptosis, we transfected cells with a plasmid encoding FKHR-green fluorescent protein (GFP). Figure 3 shows changes of the subcellular distribution of FKHR-GFP under different conditions. In proliferating glioma cells, FKHR-GFP was mostly detected in the cytoplasm of 60% of cell population and only 10% of the cells exhibited nuclear localization (Figure 3 ). After treatment with CsA or LY294002 for 24 h, the number of cells with nuclear FKHR-GFP increased significantly up to 40% and the number of cells with cytoplasmic location decreased to 35 and 25% among CsA-and LY294002-treated cells, respectively (Figure 3c ). About 30% of the cells demonstrated both nuclear and cytoplasmic localization of FKHR-GFP independent of the treatment. Staining of cells with the fluorescent dye DAPI was performed to visualize changes in the nuclear morphology. It demonstrated that the nuclear distribution of FKHR-GFP occurs in apoptotic cells with 'bean'-shaped nuclei and highly condensed chromatin in CsA-treated cultures (Figure 3a) . Among cells transfected with a plasmid encoding GFP, cytoplasmic localization was predominant, with the presence of GFP in cell processes. The treatment of transfected cells with CsA did not change subcellular localization of GFP (Figure 3b ). To determine a role of Akt in the regulation of Forkhead localization, the dominant-negative mutants interfering with Akt activity were tested by cotransfection of Akt Involvement of Akt/Forkhead pathway and FasL expression in glioma cells I Ciechomska et al constructs together with the FKHR-GFP construct. As shown in the Figure 3d , the FKHR-GFP is localized in the cytoplasm of cells transfected with wtAkt Á HA. In contrast, many cells exhibit nuclear localization of FKHR-GFP in cultures transfected with dominantnegative forms of Akt (AktK179 M and PH-Akt). The nuclear translocation of FKHR-GFP occurs due to the inhibition of endogenous Akt kinase activity. These results confirmed that the Akt kinase activity is responsible for a cytoplasmic retention of the FKHR-GFP in proliferating glioma cells. Next, we examined whether Fkhr participates in transcriptional regulation of the FasL gene during Figure 1 Inhibition of the Akt signalling pathway during CsAinduced apoptosis. (a) Western blot analysis using specific antibodies against phospho-AktThr308/Ser473, Akt, and actin was performed with total extracts from rat glioma C6 cells treated for various times with 60 mM CsA. Actin detection served as a control of equal amount of protein used in Western blot analysis. All anti-Akt antibodies were obtained from Cell Signaling, and anti-actin was obtained from Oncogene Research Products. Similar results were obtained from two independent experiments. (b) Quantitative changes in Akt phosphorylation were determined by densitometric analysis of immunoblots. Data represent average7s.e.m. of duplicate or triplicate determinations in two independent experiments. (c) Akt kinase activity (using IPAkt Kinase Assay Kit, Cell Signaling) was determined in whole-cell lysates from rat glioma C6 cells treated for various times with 60 mM CsA or 1 h with 30 mM LY294002. Using immobilized the Akt antibody, Akt kinase was selectively immunoprecipitated from whole-cell lysates (300 mg/sample). Phosphorylation of GSK-3 fusion protein by Akt kinase was detected with an anti-phospho-GSK-3a/b (Ser21/9) antibody (Cell Signaling). Akt detection served as a control of equal amount of immunoprecipitated Akt used in kinase assay (left panel). Changes in the levels of phosphoryalted and total Akt were determined in the same lysates Involvement of Akt/Forkhead pathway and FasL expression in glioma cells I Ciechomska et al apoptosis of rat C6 glioma cells. Using electrophoretic mobility shift assay (EMSA), we determined the ability of Fkhr to interact with a specific DNA sequence within the FasL promoter, termed the Forkhead-responsive element -FHRE (Brunet et al., 1999) . Nuclear extracts from untreated and CsA-treated cells were incubated with the FHRE and we observed a gradual increase of DNA binding activity after CsA treatment ( Figure 4 ). The increase of the DNA-binding activity of Fkhr was observed in cells treated with CsA at doses equal or higher than 30 mM (not shown). Two bands representing the FHRE DNA-binding activity were observed and increase of binding was easily detectable at 15 h. The levels of SP-1 DNA-binding activity measured in the same nuclear extracts (5 mg) in parallel did not change. The specificity of FHRE DNA-binding activity was verified by competition with an excess of the unlabelled FHRE probe (Figure 4 ). Preincubation of nuclear extracts with the anti-Forkhead-specific antibody abolished DNA binding activities that confirms a specificity of the binding.
Forkhead is required for transcriptional activation of FasL
Forkhead transcription factor mediates an induction of FasL expression in postmitotic neurons and PC12 cells (Brunet et al., 1999) . We have previously demonstrated that the treatment of C6 cells with CsA produces a strong activation of FasL promoter at 15-40 h after treatment (Pyrzynska et al., 2000) . In the present study, we confirmed that treatment of C6 glioma cells with 60 mM CsA evoked the increase of fasL mRNA at 20-40 h as detected by RT-PCR ( Figure 5a ). An increase in the FasL expression after CsA treatment was associated with a surface FasL protein expression as detected by flow cytometric analysis ( Figure 5b ). Malignant glioma cells, including C6 cells, express Fas receptor and are susceptible to anti-Fas antibody-mediated apoptosis (Weller et al., 1994) .
To assess the role of the Akt/Fkhr signalling pathway in the regulation of the FasL promoter during We wished to determine whether inhibition of Akt signalling is sufficient to induce FasL expression in glioma cells. The effects of 10 and 30 mM LY294002, a specific inhibitor of PI3 K (Vlahos et al., 1994) , on Akt phosphorylation were evaluated by Western blot analysis. The data in Figure 7 demonstrate that 30 mM LY294002 completely inhibited Akt phosphorylation at the Ser473 and Thr308, without any effect on the total Akt levels. The inhibition of Akt phosphorylation with LY294002 correlated with the decrease in Fkhr phosphorylation at Ser256 and an increase in the Fkhr protein level. DMSO, a solvent for LY294002, had no influence on the status of protein phosphorylation.
To elucidate whether a decrease in Akt phoshorylation and activation of Forkhead are sufficient to trigger FasL expression, we examined the effects of LY294002 on the activation of the FasL promoter and fasL mRNA accumulation in C6 glioma cells. Cells transiently Our findings demonstrating that downregulation of Akt kinase activity and activation of Forkhead transcription factor, are prerequisites for the induction of the FasL promoter in glioma cells, are of great importance for cancer therapy. Many gliomas overexpress the receptors for growth factors providing autocrine loops of stimulation and high levels of active, phosphorylated Akt have been described (Holland et al., 2000) . Moreover, PTEN is frequently deleted in human gliomas, which results in a high level of active, phosphorylated Akt (Duerr et al., 1998; Li and Sun, 1998) . PTEN, a member of a phosphatase gene family (Li et al., 1997) , plays a key role as a negative upstream regulator of Akt kinase (Maehama and Dixon, 1998; Stambolic et al., 1998; Sun et al., 1999) . PTENÀ/À murine fibroblasts are impaired in their response to apoptotic stimuli such as UV radiation and osmotic stress (Stambolic et al., 1998; Di Cristofano et al., 1999) . Members of the forkhead transcription factor family are deregulated and inactive in PTEN null cells. Moreover, a form of the Forkhead that cannot be phosphorylated by Akt is sufficient to induce growth arrest in cells with a wild-type PTEN and apoptosis in PTEN null cells (Nakamura et al., 2000) .
In glioma cells, the phosphorylated Forkhead is restrained in the cytoplasm in the presence of active Akt kinase. An application of dominant-negative mutants (AktK179M and PH-Akt), interfering with the endogenous Akt activity, releases a blockade and allows the nuclear translocation of FKHR-GFP. Many cells exhibit nuclear localization of FKHR-GFP in cultures transfected with dominant-negative Akt mutants ( Figure 5d ). The nuclear translocation of FKHR-GFP occurs due to the inhibition of endogenous Akt kinase activity. It suggests that the Akt kinase activity is responsible for a cytoplasmic retention of the FKHR-GFP in proliferating glioma cells. (a) Activity of the wild-type FasL promoter in C6 cells treated with 30 mM LY294002. C6 glioma cells were transiently transfected with a wild-type FasL promoter-luciferase and control RL-Luc. At 24 h after transfection, cells were treated with LY294002 and luciferase activities were measured using a dual-luciferase reporter assay system (Promega). Measurements of firefly luciferase activities were related to Renilla luciferase activities determined in the same extracts. Error bars represent the s.e.m. of triplicate samples. (b) Expression of fasL and gapdh mRNA in C6 glioma treated with 30 mM LY294002 was determined by RT-PCR using specific primers. A 507-bp fasL-specific sequence and 452-bp gapdh sequence were amplified from total RNA isolated from control C6 glioma cells (0), or cells treated for various times with 30 mM LY294002, or for 40 h with 60 mM CsA (control, þ ). In the negative control sample (control,À), the RT step was omitted. RT-PCR products were separated by 1.8% agarose gel electrophoresis and visualized by ethidium bromide staining
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The Akt signalling pathway controls the transcriptional activity of the members of the forkhead transcription factor family (FKHR, FKHRL1, AFX) (Brunet et al., 1999; Kops et al., 1999; Rena et al., 1999; Tang et al., 1999) . Forkhead homolog Daf-16, which controls metabolism and lifespan in the nematode C. elegans, is negatively regulated by the Akt signalling pathway (Lin et al., 1997; Ogg et al., 1997) . In many cell types, Akt directly phosphorylates Forkhead family transcription factors, which results in their cytoplasmic retention, thereby preventing them from inducing target genes (Biggs et al., 1999; Brunet et al., 1999; Brownawell et al., 2001; Suhara et al., 2002) . In most cells, activation of Forkhead leads to cell-cycle arrest and quiescence, but not apoptosis, despite the absence of Akt activity (Medema et al., 2000) . Studies of neuronal apoptosis revealed that FKHRL1 can regulate the FasL promoter in postmitotic granule neurons and differentiating PC12 cells, suggesting an involvement of these transcription factors in the regulation of cytotoxic protein expression (Brunet et al., 1999) . The suppression of Akt signalling is sufficient to induce FasL expression in vascular smooth muscle cells (VSMC) under conditions of serum deprivation (Suhara et al., 2002) . Infection of VSMC with adenoviral vector expressing a nonphosphorylatable form of FKHRL1 is able to induce FasL cell surface expression and apoptosis (Suhara et al., 2002) . We demonstrate that the treatment of glioma cells with the PI3 K inhibitor, LY294002, affects the levels of active Akt kinase and phosphorylated Fkhr leading to translocation of FKHR-GFP to the nucleus (Figures  3, 7) . However, such inhibition of Akt signalling is not sufficient to activate FasL expression (Figure 8 ) and induce cell death (not shown) in proliferating glioma cells. C6 glioma cells, as many human malignant glioma cells, possess an ability of serum-independent growth and secretion of growth factors resulting in autocrine stimulation (Hermanson et al., 1992; Saxena and Ali, 1992) . Autocrine loops of independent, prosurvival signalling pathways, like the one relying on Erk activity, operate in glioma cells and block effector pathways of apoptosis.
Although activation of Forkhead is indispensable to the induction of the FasL promoter during CsA-induced apoptosis, cooperative activation of several transcription factors activated by various signalling pathways is necessary for transcriptional induction of FasL expression. It is known that the FasL promoter can be regulated by a number of transcription factors, including NFAT (Latinis et al., 1997; Holtz-Heppelmann et al., 1998) , AP-1 and NFkB (Faris et al., 1998; Kasibhatla et al., 1998) , and Erg3 (Mittelstadt and Ashwell, 1998) depending on the cell type and stimulus. We have previously shown that CsA treatment results in the persistent activation of JNK and p38 MAP kinases leading to activation of the AP-1 transcription factor. These results suggest that cooperative action of a number of transcription factors, including Forkhead and AP-1, may participate in the activation of the FasL promoter in glioma cells. It implies that a lack of a particular component of activation will affect FasL gene induction and turn off FasL/Fas-dependent pathway of apoptosis. Our data are consistent with recent studies by Suhara et al. (2002) demonstrating that sequential activation of JNK/cJun participates in the induction of FasL expression under conditions of suppressed Akt signalling in VSMC. In CsA-induced apoptosis of glioma cells, the decrease in Akt signalling and activation of JNK/cJun pathway occur concomitantly and these events precede caspase 3 activation, which is a rather late event observed 48 h after treatment (Pyrzynska et al., 2000) .
Our studies demonstrate that Akt activity may be responsible for the restraining of the Forkhead protein in the cytoplasm of proliferating glioma cells. Since Forkhead is a transcription factor necessary for the transcriptional upregulation of FasL expression, a high level of Akt activity, possibly via a cytoplasmic retention of Forkhead, may prevent an induction of FasL expression. Human gliomas are highly resistant to current therapeutic approaches, including radiation and chemotherapy that often induce cell death via Fas-FasL system. The application of recombinant FasL (Kawaguchi et al., 2000) or adenovirus-mediated transduction of FasL induces apoptosis of malignant glioma cells (Shinoura et al., 1998; Ambar et al., 1999) , which suggests an impairment in the initiation rather than in the executory phase of Fas-mediated apoptosis in glioma cells.
To conclude, our data indicate that an inhibition of Akt signalling may be critical for Forkhead-dependent upregulation of FasL expression in glioma cells, but simultaneous or sequential activation of other transcription factors such as AP-1 is required to induce FasL expression and cell death. Pharmacological intervention with a well-known drug such as CsA, can be a useful strategy to facilitate the death of human malignant glioma cells, which are resistant to conventional therapies.
Materials and methods
Cell cultures and treatment
Rat C6 glioma cells (American Type Culture Collection) were cultured in Dulbecco's-modified Eagles's medium supplemented with 10% newborn calf serum (Sigma) and antibiotics: 50 U/ml penicillin and 50 mg/ml streptomycin. Cells were grown in 24-well or 10-cm diameter culture plates (Corning, USA) at a density of 1-4 Â 10 4 cells/cm 2 in a humidified atmosphere of CO 2 /air (5/95%). At 18 h after plating, glioma cells were treated with 60 mM CsA (Sandimmum; Sandoz; stock solution 50 mg/ml) or 10, 30 mM LY294002 (Cell Signaling, USA, stock solution 10 mM in dimethylsulfoxide -DMSO). The effects of the compounds were monitored at various times by phase-contrast microscopy.
Subcellular fractionation and Western blotting
Nuclear and whole-cell proteins were isolated as previously described (Mosieniak et al., 1998) . Protein extracts were resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and the proteins were electrotransferred on to nitrocellulose membranes. After blocking with 5% nonfat milk in TBS-T (Tris-buffered solution/0.1% Tween 20), the membranes were incubated overnight with anti-phosphoAkt-Ser473/Thr308, anti-phospho-Fkhr-Ser256, anti-phospho-GSK3b-Ser9, anti-Akt, anti-Fkhr (Cell Signaling), or anti-Actin (Oncogene Research Products) antibodies diluted in blocking buffer. The subsequent steps involved extensive washing with TBS-T and incubation for 1.5 h with 1 : 2000 diluted horseradish peroxidase-conjugated anti-rabbit IgG (Cell Signaling) or anti-mouse IgM (Oncogene Research Products) antibodies. Immunocomplexes were visualized using the enhanced chemiluminescence detection system (ECL, Amersham International).
Determination of Akt kinase activity
Akt kinase activity was determined using a nonradioactive IPAkt Kinase Assay Kit (Cell Signaling) according to the manufacturer's protocol. Briefly, using the immobilized Akt antibody, we selectively immunoprecipitated Akt kinase from whole-cell lysates (300 mg/sample) prepared from untreated cells and cells treated for various times with 60 mM CsA or cells treated with LY294002 for 1 h. Immunocomplexes of Akt kinase were incubated with 1 mg GSK-3 fusion protein in the presence of 100 mM ATP and 1 Â kinase buffer for 30 min at room temperature. An SDS-loading buffer was added to terminate the reaction, samples were boiled for 5 min, centrifuged for 2 min at 12 000 r.p.m., and resolved by SDS-PAGE. GSK-3 phosphorylation was detected with an antiphospho-GSK-3a/b (Ser21/9) antibody (Cell Signaling).
Subcellular localization of transfected FKHR-GFP
Rat C6 glioma cells (2 Â 10 4 cells/cm 2 ), grown on glass coverslips, were transfected with the FKHR-GFP construct (kindly provided by Dr TG Unterman) encoding Forkhead-GFP fusion proteins (Rena et al., 2001) or pEGFP.N1 (Clontech). At 1 day after transfection, cells were treated for 24 h with 60 mM CsA or 30 mM LY294002, PI3 K inhibitor. The cells were then fixed in 4% paraformaldehyde for 10 min at room temperature and the cell nuclei were stained with 1 mg/ml DAPI (4 0 , 6-diamidino-2-phenylindole, Sigma). After final washing in PBS, coverslips were dried and mounted on slides and visualized by fluorescence microscopy using excitation at 330-380 nm for DAPI and 450-490 nm for GFP. The number of cells exhibiting given cellular localization of FKHR-GFP was evaluated.
Analysis of DNA-binding activities
EMSA was applied to assess the DNA-binding activities of transcription factors as described previously (Kaminska et al., 1994; Kaminska et al., 1996) . Nuclear proteins (5 mg) were incubated in a binding buffer for Fkhr (20 mM HEPES, pH 7.9; 50 mM KCl; 2 mM MgCl 2 ; 0.5 mM EDTA; 10% glycerol; 0.1 mg/ml bovine serum albumin; 2 mM DTT; 0.5 mM PMSF; and 4 mg poly(dI-C) per reaction) or binding buffer for SP-1 (30 mM HEPES, pH 7.9; 100 mM KCl; 1.5 mM MgCl 2 ; 0.3 mM EDTA; 10% glycerol; 1 mM DTT; 0.5 mM PMSF, and 2.5 mg poly(dI-C) per reaction) with 0.2 ng (30 000-40 000 Cerenkov cpm) of an end-labelled probe for 20 min at room temperature. Double-stranded oligonucleotides (SIGMA-ARK, Germany) with consensus binding motifs for the transcription factors were applied: FHRE À5 0 -AATAGAT-CTTAAATAAATAGATCTTTAÀ3 0 ; SP-1 5 0 -ATTCGATC-GGGGCGGGGCGAGCÀ3 0 . Oligonucleotides were labelled with [a-32 P]dCTP by terminal transferase (Boehringer Mannheim, Germany) and purified on microspin columns (BioRad, Germany). Following incubation, 1 ml of the loading buffer containing 0.3% bromophenol blue/3% glycerol was added to the samples. The electrophoresis was performed in a nondenaturing 6% polyacrylamide gel in 1 Â TES buffer (6.7 mM Tris-HCl, pH 7.5; 1 mM EDTA; and 3.3 mM sodium acetate) at 130 V for 2 h. Gels were dried and exposed overnight to an autoradiographic film with intensifying screens at À701C.
Plasmids used for transfection
The following plasmids were used for promoter studies: wtFasL encoding firefly luciferase under control of 1.2 kb human FasL promoter; FasLmAP-1 with mutated AP-1 site (kindly provided by Dr DR Green) (Kasibhatla et al., 1998) ; and FasLDFkhr, FasL promoter with deleted Fkhr binding sites. FasLDFkhr was created from the wtFasL by removal of nucleotides À956 to À636 by HpaI and NcoI (Promega) digestion to delete the three Forkhead-binding elements located between nucleotides À858 and À836. The recessive termini were filled with a Klenow fragment of Escherichia coli polymerase I (Sigma) and ligated with the T4 DNA ligase (Sigma). The sequence was confirmed by automatic sequencing. Cotransfection with pCMV-RL, a plasmid encoding Renilla luciferase under the control of the cytomegalovirus (CMV) promoter, was used as an internal control of transfection efficiency.
The plasmids used for Akt signalling studies were: a hemagglutin-tagged wild-type Akt (wtAkt-HA), dominantnegative AktK179M Á HA and PH-Akt Á HA mutants, and a constitutively active, myristoylated Akt (MyrAkt Á HA). WtAkt Á HA, Akt K179M Á HA, and PH-Akt Á HA were kind gifts from Dr T Franke and have been described previously (Franke et al., 1995 . MyrAkt Á HA was a kind gift from Dr M Weber and has been described previously (Kulik et al., 1997) . The AktK179M Á HA construct contains a point mutation in the ATP-binding pocket of Akt rendering the kinase inactive. The PH-Akt Á HA construct contains a mutation within the plecstrin homology domain Akt and cannot be activated by PI-3K. Plasmid coding for Forkhead fused to GFP (FKHR-GFP, kindly provided by Dr TG Unterman) was employed to study the activation of the Akt signalling pathway. In some experiments, cells were cotransfected with 0.5 mg EGFP-N1 (Clontech) carrying a GFP gene under the control of the constitutive CMV promoter.
Transfection procedure and luciferase assays C6 glioma cells were cultured in 24-well plates (1 Â 10 5 cells/ well), and 24 h after plating cells were transfected using the TransFast reagent (Promega, USA) according to the manufacturer's instructions. C6 glioma cells were transfected with 0.5 mg DNA per well, which included both a control plasmid pCMV-RL and the respective constructs (wtFasL, FasLDFkhr or FasLmAP-1). To elucidate the effects of Akt overexpression on the FasL promoter, cells were cotransfected with the constructs encoding wtFasL and wtAkt or myrAkt. At 1 day after transfection, glioma cells were treated with 60 mM CsA (for 24 and 30 h) or 30 mM LY294002 (for 5, 15, and 30 h). Then cells were harvested by centrifugation or scraping the cells in a lysis buffer. Activities of the firefly and Renilla luciferases in glioma cell extracts were evaluated according to a standard protocol for the dual-luciferase reporter assay system (Promega) using a luminometer (Monolight 2010, Analytical Luminescence Laboratory, USA). The results are given as an average of the firefly luciferase activity normalized to the Renilla luciferase activity; the error bars represent the s.e.m. of triplicate samples. Data are representative of three independent experiments. Statistical comparisons of the values were performed using the two-way ANOVA test.
Evaluation of FasL expression
The expression of the rat fasL and gapdh mRNA was determined by reverse transcription of total RNA followed by PCR analysis (RT-PCR). C6 glioma cells (2 Â 10 6 ) were homogenized with 0.6 ml of RLT reagent (Qiagen) and total RNA was isolated according to the manufacturer's protocol. cDNAs were synthesized by the extension of (dT) 15 primers with 200 U of Superscript II reverse transcriptase (Gibco BRL) in a mixture containing 1 mg of total RNA. PCR amplifications were performed in a 25-ml reaction volume containing 1 mg of cDNA, dNTPs (each at 200 mM), 1 U of Taq DNA polymerase (Sigma), and 0.4 mM of each primer. The following primers were used: GAPDH (glyceraldehyde 3-phosphate dehydrogenase), sense (5 0 -ACCACAGTCCATGCCATCAC-3 0 ) and antisense (5 0 -TCCACCACCCTGTTGCTGTA-3 0 ) and FasL sense (5 0 -CAGCCCCTGAATTACCCATGTC-3 0 ) and antisense (5 0 -CACTCCAGAGATCAAAGCAGTTC-3 0 ). The amplification cycles for FasL were 941C for 1 min, 601C for 1 min, and 721C for 2 min, 30 cycles. PCR products were separated by electrophoresis on a 1.8% agarose gel and visualized by ethidium bromide staining.
The expression of surface FasL protein was confirmed by FACS analysis. C6 glioma cells were cultured in the presence of a matrix metalloproteinase inhibitor to block FasL shedding. C6 cells, untreated or treated with CsA for 25 and 50 h were harvested, centrifuged at 300 g for 5 min and resuspended in FACS buffer. Cells were then incubated with 1 mg of biotinylated anti-FasL antibody (NOK-1) for 1 h at 41C, followed by PE-labelled avidin (PharMingen). After washing with FACS buffer, the cells were analysed by flow cytometry.
